Management of transfusional iron overload in Latin America: current outlook and expert panel recommendations

Abstract The results of a meeting of physicians convening in Latin America to develop expert opinions on the diagnosis, monitoring and treatment of iron overload are as follows. An accurate diagnosis can be obtained by neonatal screening for haemoglobinopathies, especially sickle cell disease and the thalassaemias. Disease-specific registries are needed to demonstrate the extent of the problem to health authorities. Disparities in the quantity and quality of blood products must be addressed, and uniform transfusion guidelines are necessary. Serum ferritin level is a feasible marker for iron overload in the region, while magnetic resonance imaging assessment can improve the diagnosis and monitoring of cardiac and liver iron content. Medical specialists, including radiologists, pathologists and others, and health authorities, can help to implement these methods and provide adequate resources. The recently available oral deferasirox can be used to conveniently administer iron chelation to transfusional iron-overloaded patients.

[1]  Raffaella Origa,et al.  BETA THALASSEMIA , 2018, The Professional Medical Journal.

[2]  Dudley J. Pennell,et al.  Cardiovascular Magnetic Resonance , 2010, Circulation.

[3]  D. Pennell,et al.  T2* cardiovascular magnetic resonance in the management of thalassemia patients in Oman , 2009, Haematologica.

[4]  J. Bennett.  Consensus statement on iron overload in myelodysplastic syndromes , 2008, American journal of hematology.

[5]  E. Glimm,et al.  Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. , 2008, Blood.

[6]  M. Cappellini,et al.  Guidelines for the Clinical Management of Thalassaemia , 2008 .

[7]  L. Rybicki,et al.  Elevated Ferritin Is Associated with Poorer Survival Following Nonablative Allogeneic Transplantation. , 2007 .

[8]  A. Linares,et al.  Latin American Registry of Patients (Pts) with Transfusional Hemosiderosis (Th): The RELATH Study. , 2007 .

[9]  G. Ehninger,et al.  Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem-cell transplantation. , 2007, Blood.

[10]  T. Delea,et al.  Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion‐dependent thalassemia: a literature review , 2007, Transfusion.

[11]  H. Cario,et al.  Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. , 2007, Clinical therapeutics.

[12]  D. Pennell,et al.  A Randomized, Placebo-Controlled, Double-Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance , 2007, Circulation.

[13]  J. Briones,et al.  Early clinical impact of iron overload in stem cell transplantation. A prospective study , 2007, Annals of Hematology.

[14]  P. Marks,et al.  A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease , 2007, British journal of haematology.

[15]  L. Abetz,et al.  The impact of iron overload and its treatment on quality of life: results from a literature review , 2006, Health and quality of life outcomes.

[16]  S. Perrotta,et al.  A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. , 2006, Blood.

[17]  E. Neufeld.  Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. , 2006, Blood.

[18]  Y. Bertrand,et al.  Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. , 2006 .

[19]  E. Alexopoulou,et al.  Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial. , 2006, Blood cells, molecules & diseases.

[20]  J. Ford,et al.  Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. , 2006, Haematologica.

[21]  C. Hershko.  Oral iron chelators: new opportunities and new dilemmas. , 2006, Haematologica.

[22]  Z. Cabantchik,et al.  LPI-labile plasma iron in iron overload. , 2005, Best practice & research. Clinical haematology.

[23]  E. Hellström-Lindberg.  Management of anemia associated with myelodysplastic syndrome. , 2005, Seminars in hematology.

[24]  T. S. St. Pierre,et al.  Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. , 2005, Blood.

[25]  M. Cazzola,et al.  P-113 The efficacy and tolerabilityof ICL670, a once-daily oral iron chelator, in patients with myelodysplastic syndrome (MDS) and iron overload , 2005 .

[26]  D. Pennell,et al.  Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance , 2004, British journal of haematology.

[27]  R. Nagel,et al.  Sickle-cell disease , 2004, The Lancet.

[28]  I. Papassotiriou,et al.  Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease , 2004, British journal of haematology.

[29]  Z. Cabantchik,et al.  Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator. , 2004, Blood.

[30]  P. Jarritt,et al.  Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. , 2004, Blood.

[31]  C. Cervellati,et al.  Oxygen, reactive oxygen species and tissue damage. , 2004, Current pharmaceutical design.

[32]  A. Stanley,et al.  Abnormal liver function tests following bone marrow transplantation: aetiology and role of liver biopsy , 2004, European journal of gastroenterology & hepatology.

[33]  J. D. Johnston.  Non-invasive assessment of hepatic iron stores by MRI. , 2004, Annals of clinical biochemistry.

[34]  A. Cnaan,et al.  Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. , 2004, Haematologica.

[35]  A. Hoffbrand,et al.  Role of deferiprone in chelation therapy for transfusional iron overload. , 2003, Blood.

[36]  E. Neufeld,et al.  Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial , 2003, The Lancet.

[37]  M. Essink‐bot,et al.  Quality of life measurement in patients with transfusion‐dependent myelodysplastic syndromes , 2003, British journal of haematology.

[38]  G. Mufti,et al.  Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes , 2003, British journal of haematology.

[39]  G. Brittenham,et al.  Noninvasive measurement of iron: report of an NIDDK workshop. , 2003, Blood.

[40]  J. Briones,et al.  Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation , 2002, Bone Marrow Transplantation.

[41]  D N Firmin,et al.  Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. , 2001, European heart journal.

[42]  J. Porter.  Practical management of iron overload , 2001, British journal of haematology.

[43]  E. Vichinsky.  Consensus document for transfusion-related iron overload. , 2001, Seminars in hematology.

[44]  P. Harmatz,et al.  Severity of Iron Overload in Patients with Sickle Cell Disease Receiving Chronic Red Blood Cell Transfusion Therapy , 2000, Blood.

[45]  Matthew Darlison,et al.  Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register , 2000, The Lancet.

[46]  J. Porter,et al.  Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemia , 2000 .

[47]  F. Galactéros.  [Secondary iron overload]. , 1998, La Revue du praticien.

[48]  M. Cazzola,et al.  A moderate transfusion regimen may reduce iron loading in beta‐ thalassemia major without producing excessive expansion of erythropoiesis , 1997, Transfusion.

[49]  P. Lane.  Sickle cell disease. , 1996, Pediatric clinics of North America.

[50]  Rm,et al.  Sickle cell disease , 1996 .

[51]  A. Piga,et al.  Results of long-term iron-chelating therapy. , 1996, Acta haematologica.

[52]  A. Hoffbrand,et al.  Results of long‐term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators , 1995, British journal of haematology.

[53]  M. Cazzola,et al.  Relationship between transfusion regimen and suppression of erythropoiesis in β‐thalassaemia major , 1995, British journal of haematology.

[54]  J. H. MacMillan,et al.  Survival in Medically Treated Patients with Homozygous β-Thalassemia , 1994 .

[55]  C. McLaren,et al.  Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. , 1994, The New England journal of medicine.

[56]  J. H. MacMillan,et al.  Survival in medically treated patients with homozygous beta-thalassemia. , 1994, The New England journal of medicine.